Management of Women with Polycystic Ovary Syndrome During Pregnancy
Copyright © 2020 Elsevier Inc. All rights reserved..
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among reproductive age women and is associated with subfertility and adverse perinatal outcomes, which may include early pregnancy loss, gestational diabetes mellitus, hypertensive spectrum disorder, preterm birth, fetal growth disorders, and cesarean deliveries. The phenotypic heterogeneity, different diagnostic criteria, and PCOS-related conditions that women enter pregnancy with have limited evidenced-based studies and guidelines to reduce pregnancy complications among this high-risk population. This review summarizes the available evidence on the approach and management of women with PCOS preconception, prenatal, and postpartum.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Endocrinology and metabolism clinics of North America - 50(2021), 1 vom: 01. März, Seite 57-69 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Valent, Amy M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 25.10.2021 Date Revised 25.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ecl.2020.10.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320794490 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320794490 | ||
| 003 | DE-627 | ||
| 005 | 20231225174355.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ecl.2020.10.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320794490 | ||
| 035 | |a (NLM)33518186 | ||
| 035 | |a (PII)S0889-8529(20)30083-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Valent, Amy M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of Women with Polycystic Ovary Syndrome During Pregnancy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.10.2021 | ||
| 500 | |a Date Revised 25.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among reproductive age women and is associated with subfertility and adverse perinatal outcomes, which may include early pregnancy loss, gestational diabetes mellitus, hypertensive spectrum disorder, preterm birth, fetal growth disorders, and cesarean deliveries. The phenotypic heterogeneity, different diagnostic criteria, and PCOS-related conditions that women enter pregnancy with have limited evidenced-based studies and guidelines to reduce pregnancy complications among this high-risk population. This review summarizes the available evidence on the approach and management of women with PCOS preconception, prenatal, and postpartum | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Metformin | |
| 650 | 4 | |a Perinatal management | |
| 650 | 4 | |a Polycystic ovary syndrome | |
| 650 | 4 | |a Pregnancy complications | |
| 700 | 1 | |a Barbour, Linda A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrinology and metabolism clinics of North America |d 1996 |g 50(2021), 1 vom: 01. März, Seite 57-69 |w (DE-627)NLM013004832 |x 1558-4410 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2021 |g number:1 |g day:01 |g month:03 |g pages:57-69 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ecl.2020.10.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2021 |e 1 |b 01 |c 03 |h 57-69 | ||